YAP1 and laryngeal carcinoma: Recent studies have demonstrated that PRMT 1, a type I PRMT, functions as a positive regulator of YAP1 activity in chondrosarcoma (10), while PRMT5, a type II PRMT, promotes laryngeal cancer cell growth and its invasive capacity through the LATS2 and YAP1 signaling pathways (11).